ENGLISH | 中文
R&D Investments by America's Pharmaceutical Research Companies Near Record $40 Billion in 2005
  
Share :  
  • Washington    February 13, 2006

  •  
  • Washington, D.C. — New statistics released today show that R&D investments in new medicines by PhRMA's biotechnology and pharmaceutical research member companies reached a record $39.4 billion in 2005 (up from $37 Billion in 2004), according to PhRMA's Annual Member Survey. The increased investment in biomedical R&D in 2005 continues 25 years of strong growth in R&D investments by America's research-based pharmaceutical companies – up from $2 billion in 1980. The total investments in biotechnology and pharmaceutical R&D by both PhRMA member companies and non-PhRMA members reached a record $51.3 billion in 2005.

    America's research-based biopharmaceutical companies once again lead the world in investing in the hunt for new cures and treatments. Research companies are working everyday to save lives, end disease and relieve pain. The R&D investment made by PhRMA member companies ensures innovative medicines to meet patient needs, and the steady growth of R&D investment continues to support important advances in better medicines and new treatments for patients made by research scientists and physicians.

    Pfizer in one of the member of PhRMA. We dedicate ourselves to make people live a longer, healthier and happier life with the steady growth of R&D investment. Pfizer's R&D investment is over $7.4 billion in 2005. China is an important market for Pfizer. Pfizer established Pfizer China R&D Center in Shanghai in October 2005. The state-of-the-art facility will provide drug development support capabilities and biometric expertise to China and the Asian region. Pfizer's planned investment into this R&D center will near US$25 million over the next 5 years. Pfizer is committed to China, both in terms of serving the broader health care needs of its patients as well as advancing the country's scientific and research capabilities. This is evidenced by the establishment of the research and development center in Shanghai as well as our goal to introduce some 20 new medications to China by 2010.


Text SizeAAA